Inventors with similar research interests:
Company Filing History:
51 out of 525 
31 out of 559 
26 out of 52 
Years Active: 1992-2025
Introducing Gerd Ritter: Pioneering Innovator in Therapeutic Antibodies
Gerd Ritter, a prominent inventor based in New York, NY, has made significant contributions to the field of biomedical research with his groundbreaking patents related to therapeutic antibodies. With an impressive portfolio of 55 patents, Ritter has undoubtedly left an indelible mark on the medical industry.
Among his latest inventions is the development of anti-CTLA-4 antibodies that specifically target CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a molecule involved in regulating immune responses. These antibodies not only bind to human CTLA-4 but also act as antagonists, effectively inhibiting its function. Ritter's patent encompasses the use of these antibodies in pharmaceutical compositions, along with related nucleic acids, expression vectors, and host cells. The applications of this invention extend to treating various conditions by modulating the CTLA-4 pathway.
In addition to his work on CTLA-4 antibodies, Ritter has also contributed to the field with his invention of antibodies targeting the human OX40 receptor (OX40). These antibodies selectively bind to OX40 and modulate its activity, either enhancing, activating, or inducing it, or reducing, deactivating, or inhibiting it. The patent covers the use of these anti-OX40 antibodies to treat disorders such as cancer, autoimmune diseases, and inflammatory disorders. This innovation holds significant potential in advancing immunotherapy and improving patient outcomes.
Throughout his career, Ritter has been associated with reputable organizations in the biotech and healthcare sectors. He has made significant contributions to Agenus Inc., a leading biopharmaceutical company focused on developing innovative immune-based treatments for cancer. Ritter's collaboration with MEMORIAL SLOAN KETTERING CANCER CENTER, one of the world's premier cancer research and treatment institutions, further demonstrates his commitment to advancing scientific knowledge in the context of translational medicine.
Notably, Ritter has worked alongside esteemed colleagues, including Lloyd J Old and Marc Van Dijk. Their combined expertise and collaborative efforts have undoubtedly propelled the field of therapeutic antibodies forward, paving the way for novel treatments and improved patient care.
Gerd Ritter's extensive patent portfolio and groundbreaking research make him an eminent figure in the world of biomedical innovation. His discoveries in the realm of therapeutic antibodies offer promising avenues for the treatment of cancer and various immune-related diseases. We eagerly await more groundbreaking inventions from this visionary inventor, as he continues to revolutionize the healthcare landscape.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.